L01EX09 • nintedanib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Nintedanib is a medication used for the treatment of idiopathic pulmonary fibrosis and other progressive interstitial lung diseases. It is a tyrosine kinase inhibitor that works by reducing inflammation and fibrosis in the lungs.
The medication is taken orally, usually twice daily with meals. The dose is adjusted based on the patient's tolerance and any adverse reactions. Common side effects include diarrhea, nausea, vomiting, and decreased appetite.
Nintedanib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe liver impairment.
This medication is an important option for patients with progressive lung diseases, helping to slow disease progression and improve their quality of life.
Substance: nintedanib
Date of last drug list: 01-05-2026
Commercial code: W70173002
Concentration: 150mg
Pharmaceutical form: soft capsules
Quantity: 60
Product type: generic
Price: 6707.28 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: PHARMADOX HEALTHCARE LIMITED - MALTA
Holder: TEVA PHARMACEUTICALS S.R.L. - MALTA
Number: 15368/2024/02
Shelf life: 3 years
NHP 6.20 (C2) - Idiopathic pulmonary fibrosis
Price
Copayment
Patient
6707.28 RON
6707.28 RON
0.00 RON